RT Journal Article
SR Electronic
T1 Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.03.20167502
DO 10.1101/2020.08.03.20167502
A1 Koller, Dora
A1 Almenara, Susana
A1 Mejía, Gina
A1 Saiz-Rodríguez, Miriam
A1 Zubiaur, Pablo
A1 Román, Manuel
A1 Ochoa, Dolores
A1 Wojnicz, Aneta
A1 Martín, Samuel
A1 Romero-Palacián, Daniel
A1 Navares-Gómez, Marcos
A1 Abad-Santos, Francisco
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.03.20167502.abstract
AB Objective To assess adverse events and safety of aripiprazole and olanzapine treatment.Methods Twenty-four healthy volunteers receiving 5 daily oral doses of 10 mg aripiprazole and 5 mg olanzapine in a crossover clinical trial were genotyped for 46 polymorphisms in 14 genes by qPCR. Drug plasma concentrations were measured by HPLC-MS/MS. Blood pressure and 12-lead ECG were measured in supine position. Adverse events were also recorded.Results Aripiprazole decreased diastolic blood pressure on the first day and decreased QTc on the third and fifth day. Olanzapine had a systolic and diastolic blood pressure, heart rate and QTc lowering effect on the first day. Polymorphisms in ADRA2A, COMT, DRD3 and HTR2A genes were significantly associated to these changes. The most frequent adverse drug reactions to aripiprazole were somnolence, headache, insomnia, dizziness, restlessness, palpitations, akathisia and nausea while were somnolence, dizziness, asthenia, constipation, dry mouth, headache and nausea to olanzapine. Additionally, HTR2A, HTR2C, DRD2, DRD3, OPRM1, UGT1A1 and CYP1A2 polymorphisms had a role in the development of adverse drug reactions.Conclusions Olanzapine induced more cardiovascular changes; however, more adverse drug reactions were registered to aripiprazole. In addition, some polymorphisms may explain the difference in the incidence of these effects among subjects.Competing Interest StatementF. Abad-Santos and D. Ochoa have been consultants or investigators in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, Cinfa, FAES, Farmalider, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Silverpharma, Teva and Zambon. The remaining authors declare no conflict of interest.Clinical TrialEUDRA-CT: 2018-000744-26Funding StatementD. Koller is co-financed by the H2020 Marie Sklodowska-Curie Innovative Training Network 721236 grant. M. Navares is co-financed by the Consejeria de Educacion, Juventud y Deporte PEJ-2018-TL/BMD-11080 grant from Comunidad de Madrid and Fondo Social Europeo.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Research Ethics Committee of Hospital de La Princesa (CEIC) authorized by the Spanish Drugs Agency and under the guidelines of Good Clinical Practice and the Declaration of HelsinkiAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe details about the study are available on the webpage of the Spanish Agency of Medicines and Health Products. https://reec.aemps.es/reec/public/detail.html